How should I interpret and work up a CBC showing leukocytosis, thrombocytosis, and lymphocytosis?

Interpretation and Workup of CBC Abnormalities

This CBC pattern showing mild leukocytosis (WBC 13.5), marked thrombocytosis (platelet 534), and absolute lymphocytosis (4,793) that has remained relatively stable over 4 months requires immediate flow cytometry to rule out chronic lymphocytic leukemia (CLL) or a myeloproliferative neoplasm (MPN), particularly essential thrombocythemia (ET).

Initial Interpretation

Your CBC shows three concurrent abnormalities:

• Leukocytosis: WBC 13.5 (was 11.6) - mild elevation
• Thrombocytosis: Platelets 534 (was 550) - sustained elevation >450 × 10⁹/L
• Absolute lymphocytosis: 4,793 (was 4,686) - approaching the 5,000 threshold

The stability of these values over 4 months is particularly significant, as reactive processes typically fluctuate more dramatically 1.

Primary Diagnostic Considerations

1. Chronic Lymphocytic Leukemia (CLL)

The absolute lymphocyte count of 4,793 is critically close to the diagnostic threshold for CLL, which requires ≥5,000 B lymphocytes/L sustained for at least 3 months 2, 3. The diagnosis of CLL requires flow cytometry to confirm clonality and characteristic immunophenotype (CD5+, CD19+, CD20+, CD23+, with low surface immunoglobulin) 2, 3.

If the lymphocyte count is <5,000 but clonal B cells are present without lymphadenopathy or organomegaly, this would be classified as monoclonal B-lymphocytosis (MBL), which progresses to CLL requiring treatment at 1-2% per year 2, 4.

2. Myeloproliferative Neoplasm (MPN)

The sustained thrombocytosis (>450 × 10⁹/L for 4 months) raises concern for essential thrombocythemia (ET). WHO criteria for ET require sustained platelet count ≥450 × 10⁹/L, bone marrow biopsy showing megakaryocytic proliferation, exclusion of other MPNs, and demonstration of JAK2 V617F or other clonal marker 5.

The concurrent mild leukocytosis and lymphocytosis could represent either a separate process or be part of the MPN picture.

Immediate Workup Algorithm

Step 1: Flow Cytometry (URGENT)

• Peripheral blood flow cytometry to assess for:
  • B-cell clonality (kappa/lambda light chain restriction)
  • CLL immunophenotype (CD5+/CD19+/CD20+/CD23+)
  • Exclude mantle cell lymphoma (CD5+/CD23-)
  • This is diagnostic for CLL and can be performed on peripheral blood alone 2, 6

Step 2: Peripheral Blood Smear Review

• Examine lymphocyte morphology:
  • Monomorphic population suggests lymphoproliferative disorder
  • Polymorphic population suggests reactive process 7, 8
• Look for small mature lymphocytes with narrow cytoplasm and smudge cells (characteristic of CLL) 2
• Assess for megakaryocyte fragments or abnormal platelet morphology

Step 3: Additional Laboratory Tests

• Complete metabolic panel including LDH (elevated in lymphoproliferative disorders)
• Serum protein electrophoresis and quantitative immunoglobulins
• Direct antiglobulin test (DAT) to assess for autoimmune hemolysis 2
• Hepatitis B, C, and HIV serology (required before potential treatment) 6

Step 4: If Flow Cytometry Confirms CLL

• FISH panel for del(17p), del(11q), del(13q), trisomy 12 4
• TP53 mutation analysis (critical for treatment decisions) 6
• IGHV mutation status (prognostic and guides therapy selection) 4
• Physical examination for lymphadenopathy, hepatosplenomegaly
• Staging using Rai or Binet system 2, 6

Step 5: If CLL is Excluded - Pursue MPN Workup

• JAK2 V617F mutation testing (present in ~50% of ET cases) 5
• Bone marrow biopsy with cytogenetics to:
  • Confirm megakaryocytic proliferation
  • Exclude BCR-ABL1 (chronic myeloid leukemia)
  • Exclude myelodysplastic syndrome
  • Assess for myelofibrosis 5
• BCR-ABL1 testing (qualitative RT-PCR) to exclude CML 9

Critical Pitfalls to Avoid

1. Do not wait for lymphocyte count to reach 5,000 - Flow cytometry should be performed now to detect MBL or early CLL 4

2. Do not assume reactive thrombocytosis - While iron deficiency, infection, and inflammation can cause thrombocytosis, the 4-month persistence and concurrent lymphocytosis mandate clonal evaluation 5

3. Do not order bone marrow biopsy initially for CLL - Diagnosis can be made from peripheral blood flow cytometry alone; bone marrow is only needed if flow cytometry is inconclusive or before starting certain therapies 6

4. Do not miss mantle cell lymphoma - This CD5+ lymphoma can mimic CLL but is CD23-negative and requires different treatment 2

When to Refer to Hematology/Oncology

Immediate referral is indicated if:

• Flow cytometry confirms clonal B-cell population (regardless of count)
• Lymphocyte count reaches ≥5,000
• Constitutional symptoms develop (fever, night sweats, weight loss)
• Lymphadenopathy or splenomegaly on examination
• Cytopenias develop (anemia or true thrombocytopenia)

Referral within 2-4 weeks if:

• Thrombocytosis persists without clear reactive cause
• Leukocytosis continues to rise
• Flow cytometry and initial workup are negative but counts remain abnormal

Monitoring if Initial Workup is Negative

If flow cytometry is negative and no clonal disorder is identified:

• Repeat CBC with differential in 3 months
• Investigate and treat potential reactive causes (infection, inflammation, iron deficiency)
• Consider repeat flow cytometry if lymphocyte count increases or approaches 5,000
• Monitor for development of symptoms or physical findings